EU regulators have delayed a decision to approve Novavax’s variant-tailored Covid-19 vaccine, Financial Times reports.
(Bloomberg) — EU regulators have delayed a decision to approve Novavax’s variant-tailored Covid-19 vaccine, Financial Times reports.
- The European Medicines Agency, which was due to approve the updated jab last Friday, requested more information
- Novavax said the agency has additional questions, which the company is “answering expeditiously”
- The EMA has questions on the potency of the latest version of the vaccine and seeks to ensure its characteristics are the same across different production sites: FT, citing one unidentified person with knowledge of the talks
- The EMA declined to comment to the FT
To view the source of this information, click here
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.